TY - JOUR
T1 - In Vitro Inhibition of Replication of Dengue Virus Serotypes 1–4 by siRNAs Bound to Non-Toxic Liposomes
AU - Rodriguez-Salazar, Carlos Andrés
AU - Recalde-Reyes, Delia Piedad
AU - Bedoya, Juan Pablo
AU - Padilla-Sanabria, Leonardo
AU - Castaño-Osorio, Jhon Carlos
AU - Giraldo, Maria Isabel
N1 - Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2022/2
Y1 - 2022/2
N2 - Dengue virus is a ssRNA+ flavivirus, which produces the dengue disease in humans. Cur-rently, no specific treatment exists. siRNAs regulate gene expression and have been used systemat-ically to silence viral genomes; however, they require controlled release. Liposomes show favorable results encapsulating siRNA for gene silencing. The objective herein was to design and evaluate in vitro siRNAs bound to liposomes that inhibit DENV replication. siRNAs were designed against DENV1–4 from conserved regions using siDirect2.0 and Web-BLOCK-iT™ RNAiDesigner; the ini-tial in vitro evaluation was carried out through transfection into HepG2 cells. siRNA with silencing capacity was encapsulated in liposomes composed of D-Lin-MC3-DMA, DSPC, Chol. Cytotoxicity, hemolysis, pro-inflammatory cytokine release and antiviral activity were evaluated using plaque assay and RT-qPCR. A working concentration of siRNA was established at 40 nM. siRNA1, siRNA2, siRNA3.1, and siRNA4 were encapsulated in liposomes, and their siRNA delivery through lipo-somes led to a statistically significant decrease in viral titers, yielded no cytotoxicity or hemolysis and did not stimulate release of pro-inflammatory cytokines. Finally, liposomes were designed with siRNA against DENV, which proved to be safe in vitro.
AB - Dengue virus is a ssRNA+ flavivirus, which produces the dengue disease in humans. Cur-rently, no specific treatment exists. siRNAs regulate gene expression and have been used systemat-ically to silence viral genomes; however, they require controlled release. Liposomes show favorable results encapsulating siRNA for gene silencing. The objective herein was to design and evaluate in vitro siRNAs bound to liposomes that inhibit DENV replication. siRNAs were designed against DENV1–4 from conserved regions using siDirect2.0 and Web-BLOCK-iT™ RNAiDesigner; the ini-tial in vitro evaluation was carried out through transfection into HepG2 cells. siRNA with silencing capacity was encapsulated in liposomes composed of D-Lin-MC3-DMA, DSPC, Chol. Cytotoxicity, hemolysis, pro-inflammatory cytokine release and antiviral activity were evaluated using plaque assay and RT-qPCR. A working concentration of siRNA was established at 40 nM. siRNA1, siRNA2, siRNA3.1, and siRNA4 were encapsulated in liposomes, and their siRNA delivery through lipo-somes led to a statistically significant decrease in viral titers, yielded no cytotoxicity or hemolysis and did not stimulate release of pro-inflammatory cytokines. Finally, liposomes were designed with siRNA against DENV, which proved to be safe in vitro.
KW - Dengue virus
KW - Liposomes
KW - SiRNA
UR - http://www.scopus.com/inward/record.url?scp=85124505028&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85124505028&partnerID=8YFLogxK
U2 - 10.3390/v14020339
DO - 10.3390/v14020339
M3 - Article
C2 - 35215929
AN - SCOPUS:85124505028
SN - 1999-4915
VL - 14
JO - Viruses
JF - Viruses
IS - 2
M1 - 339
ER -